Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYMN trial
ISRCTN85785327Phase 3Terminated
- Sponsor
- University College London
- Start
- Jun 2009
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
01
Overview
Phase 3, randomised, open-label trial of mitomycin c and bcg vaccine in non-muscle-invasive bladder cancer (NMIBC) (2 arms), sponsored by University College London. Primary endpoints: Disease-free survival and Complete response rate at 3 months. Started Jun 2009; status: terminated.
02
Drugs
mitomycin cbcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ISRCTN85785327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN85785327.